

Date: August 2, 2023

BSE Limited P J Towers, Dalal Street, Mumbai – 400 001

Script Code: 543904

National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051

Symbol: MANKIND

Dear Sir/ Madam,

Subject : Investor Presentation

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the investor presentation on financial results of Q1FY23-24.

The presentation is also being uploaded on the website of the company i.e. www.mankindpharma.com.

You are requested to kindly take the above information on your records.

Thanking You,

Yours Faithfully,

For Mankind Pharma Limited

Pradeep Chugh Company Secretary and Compliance Officer Membership No. A18711



INVESTOR PRESENTATION Q1FY24

P.C

Safe Harbour Statement



The statements, are as on date and may contain forward-looking statements like the words "believe", "expect", "anticipate", "intend", "plan", "estimate", "project", "will", "may", "targeting" and similar expressions regarding the financial position, business strategy, plans, targets and objectives of the Company. Such forward-looking statements involve known and unknown risks which may cause actual results, performance or achievements to be materially different from results or achievements expressed or implied. The risks and uncertainties inter-alia, relating to these statements include (i) cash flow projections, (ii) industry and market conditions; (iii) ability to manage growth; (iv) competition; (v) government policies and regulations; (vi) obtaining regulatory approvals; (vii) domestic & international economic conditions such as interest rate & currency exchange fluctuations; (viii) political, economic, legal and social conditions in India/ elsewhere; (ix) technological advances; (x) claims and concerns about product safety and efficacy; (xi) domestic and foreign healthcare reforms; (xii) inability to build production capacity; (xiii) unavailability of raw materials and failure to gain market acceptance.

The Company shall not have any responsibility or liability whatsoever for any loss howsoever arising from this presentation or its contents or otherwise arising in connection therewith.

Index

Corporate Framework

- Mankind at a Glance
- Key Strengths
- Strategy Going Ahead



Business Updates

- Domestic Business
- Consumer Healthcare Business
- Export Business

02

01

Financial Performance

- Key Financial Snapshot Q1FY24
- Quarterly P & L Highlights
- Key Financial Metrics

04 Additional Information

- Key Performance Indicators
- Environment, Social, Governance (ESG)
- Shareholding Pattern
- Q1FY24 Earnings Call Details
- Annexure Formulae



Corporate Framework


Manking Side





Market Leadership	#1 Rank in Prescriptions over the last five years*	Youngest in Top 5 of the IPM*	#4 By value in the IPM*	4 Consumer Healthcare brands ranked #1 in their categories*
Scale	INR 8,749 Crore FY23 Revenue	97% Domestic revenue	20 # of INR 100 Cr+ brand families*	15,000+ Field force***
Growth	19% Revenue CAGR FY21-23	18% Domestic Business Revenue CAGR FY21-23	3x Domestic Average volume growth for FY 21-23 vs IPM*	22% Consumer Healthcare Revenue CAGR FY21-23
Profitability and Capital Efficiency	21.9% FY23 EBITDA Margin	15.0% FY23 PAT Margin	25% / 40% FY23 ROCE** / Adj ROCE**	23% / 39% FY23 ROE** / Adj ROE**

*As per IQVIA, MAT March 2023; ** Refer Annexure for Formulae; ***includes field managers



*As per IQVIA, MAT March 2023

Strategy Going Ahead



Increase the value of prescriptions in existing markets of strength by expanding market coverage; CVM moved from 62% in FY21 to 68% in FY23*

Increasing share of chronic segment by growing presence in existing therapies (Insulin Glargine) and expansion into new therapies (Respiratory, CNS, Transplant)

Increase penetration in Metros/Tier I cities by engaging Key Opinion Leaders, hospital tie-ups and specialty division launches (10 divisions launched in last 24 months)

International DMF Quality API, bringing DMF quality medicines at Indian prices; 101 SKUs launched till date

ii E®E

Grow consumer healthcare business leveraging existing brand equity, additional distribution models, Rx to OTX/OTC switches (HealthOK)

Build alternative channels of growth including e-commerce and other contemporary trade channels; ~5% in FY23

2

Continue to develop digital platforms to enhance doctor engagement medical content (Docflix); launch of next generation AI based Sales Force Automation Tool



Financial Performance

Key Financial Snapshot - Q1FY24

Capital

28%


ROCE*

25%

ROE*

Financials / Growth **Margins** Efficiency 18% 2,579 Revenue (INR cr) **YoY Growth** 43% 660 / 25.6% YoY Growth EBITDA (INR Cr)/Margin 494 / 19.2% 66% PAT (INR Cr)/Margin **YoY Growth**

Segmental Revenue Break - Up





Mr. Rajeev Juneja Vice Chairman & Managing Director

"We have started the year on a healthy note, with strong double digit growth in sales and profitability. The Pharma segment outperformed the IPM by 1.5X led by volume growth and highest ever chronic share. Our consumer healthcare segment maintained dominant brand leadership in respective categories. We have also seen positive results of our prior initiatives to improve profitability, with EBITDA growing 43% YoY. Our market disruptive "DMF Quality Products" campaign has seen an outstanding response and we are rapidly expanding our product offerings in this important drive. Our strategic initiatives across the businesses are delivering positive results and we are hopeful that we will continue to outperform industry growth, going ahead".




Quarterly P&L Highlights




INR Crore	Q1FY24	Q1FY23	YoY Growth	Q4FY23	QoQ Growth
Revenue from Operations	2,579	2,180	18%	2,053	26%
Domestic Business	2,419	2,129	14%	1,972	23%
Consumer Healthcare	208	193	8%	152	37%
Exports Business	160	51	214%	81	98%
Gross Profit	1,759	1,425	23%	1,379	28%
EBITDA	660	460	43%	419	57%
Profit After Tax	494	298	66%	294	68%
Diluted EPS* (INR)	12.1	7.3	66%	7.1	70%
Cash EPS* (INR)	14.3	9.3	54%	9.2	55%
Gross Margins %	68.2%	65.4%		67.2%	
EBITDA Margins %	25.6%	21.1%		20.4%	
PAT Margins %	19.2%	13.7%		14.3%	


Key Financial Metrics






ROE*






Cash Flow from Operations (INR crore)




Net Operating Working Capital Days*

ROCE*

28%



CAPEX (INR crore)






Business Updates

Domestic Business - Continued Outperformance









Volume Outperformance of 3.2X

Domestic Business witnessed a growth of 14%* YoY in Q1FY24

• Secondary Sales growth of 12.5%, versus 8.5% growth in the IPM (1.5X outperformance)

Maintained #4 rank with market share of 4.4% in Q1FY24 as compared to 4.2% in Q1FY23

- Ranked #2 in CVM with market share increasing to 6.5% in Q1FY24 from 6.3% in Q1FY23
- Volume growth of 4.3% as compared to 1.4% for the IPM, outperformance of 3.2X
- Chronic growth of 17% as compared to IPM growth of 10% in Q1FY24
 - Chronic share increased to 36% in Q1FY24 as compared to 34% in Q1FY23 and 35% in Q4FY23

Maintained #1 rank in prescription with 15.4% share in Q1FY24 versus 15.1% in Q1FY23

• Prescriber Penetration increased to 82.4% in Q1FY24 from 81.2% in Q1FY23

Panacea secondary sales growth of 22% YoY in Q1FY24

Increasing Share of Chronic Segment



17

10

Q1FY24

Increasing share of chronic segment that has a higher price realisation and lifetime value

19

13

FY22

Consistent focus to increase chronic contribution



Q1FY23


Mankind Chronic Growth %

14

11

FY23

IPM Chronic Growth %




Chronic Contribution %

Growth driven by expanding presence in Metro & Tier I

.. Across a Fast Growing Diversified Portfolio




Diversified Therapy Presence (Sales Mix – Q1FY24)



High Ranks across Acute and Chronic Areas

Therapy Areas	Rank in CVM	FY 20-23 CAGR		
	(Q1FY24)	Mankind	IPM	
Anti-Infectives	4	11%	8%	
Cardiovascular	3	17%	11%	
Respiratory	6	16%	12%	
Anti Diabetic	4	16%	8%	
Urology	1	17%	12%	
Gynaecology	2	30%	12%	
Overall	2	13%	10%	

Growth outperformance in multiple segments - Q1FY24




IPM Growth Rate % Mankind Growth Rate %

Building Fast Growing Consumer Healthcare Franchise...



Consumer Healthcare Segment Revenue



- Consumer Healthcare segment witnessed a growth of 8% YoY and 37% QoQ
- Secondary sales in Prega News[®],HealthOK[™], Manforce[®] condoms up by 30%* YoY, 23%* YoY, 11%* YoY respectively in Q1FY24
- 4 consumer healthcare brands ranked #1 in their categories*
- Consistent investment in brand building
 - Increasing presence across Modern Trade, E-commerce and Q-Commerce channels
 - Focused print, TV and digital campaigns to enhance brand recall
- Focus on increasing rural penetration in key brands Manforce[®] Condoms, Gas-o-Fast[®] and Prega News[®]

Leverage existing brand equity to launch brand extensions - Prega News® launched Preganews Advance, Ovanews, PregaHope & Pregahappy

Position Prega News® as "Expert Pregnancy Care Solution Brand"







#1 Condom Brand Market Share – 30%



#1 Pregnancy Test Kit Brand **Market Share - 85%**



#2 Antacid Powder Brand **Market Share - 8%**

Mankind's HealthOK MULTIVITAMIN TABLETS

#8 Vitamins, Minerals, Nutrients Brand **Market Share - 3%** UNWANTED-72

#1 Emergency Contraceptive Brand Market Share – 60% **AcneStar**Gel

#1 Medicated Anti-Acne Brand Market Share – 33%



DMF Quality Products At Mankind Prices



First Company in India to offer DMF Quality API products at affordable prices



Driven by the spirit of serving every Indian, Mankind Pharma makes world's best quality medicines (DMF quality) accessible and affordable to one and all.

Scan to know more

Visit us at: www.mankindpharma.com | Follow us on: 📑 😏 📊 🞯

Mankind Pharma Sets New Industry Standard with Unprecedented Display on Burj Khalifa, Reinforcing **Commitment to Excellence**




Strong Corporate Identity Complements Brand Recall...



Strategically selected national and regional brand ambassadors

Corporate Brand Ambassadors

Consumer Healthcare Brand Ambassadors



...With Targeted Marketing Initiatives



MAN force[®]

India's No.1* brand for condoms -

NO. Condom Brand


एक

The idea behind the campaign was to populate the idea of vast range of flavors & textures offered by the brand



Prega News - Means Good News

Targeted 360 degree communication with video sequencing Ads; • Optimizing the complete marketing funnel from awarenessconsideration- purchase intent to ensure customer activation



...With Targeted Marketing Initiatives





Gas-O-Fast - India Ki Acidity Ka Asli Indian Solution

• Launched a 360 degree campaign in TV, Print, Radio, Digital & OOH to amplify the brand message of trusting only Asli Jeera of Gas-o-Fast. Sampling of 6,00,000 quantity done in Q1 FY24



HealthOK - To drive brand awareness & connect at regional level

- Ads in newspaper in the market of U.P.
- Participated in events like Kanpur Marathon & Pandharpur Yatra
- Branding & Sampling conducted
 - 1,00,000 samples distributed in Maharashtra & marathon in U.P.








Exports Business Update





Exports business witnessed a growth of 214% YoY in Q1FY24 aided by certain one-off opportunities in the US

- Focus on differentiated filings, including in-licensing for key markets
- New integrated API/formulation manufacturing plant expected to be commercialized in H1FY24
 - Exploring export of Dydrogesterone to key markets



Additional Information

Key Performance Indicators (as per ICDR Requirement post IPO)



	FY22	FY23	Q1FY23	Q1 FY24
Revenue from Operations within India as a percentage of revenue from operations %	97.60%	96.62%	97.66%	93.79%
EBITDA* (INR Million)	20,038.00	19,130.61	4,596.78	6,595.41
EBITDA Margin (%)	25.75%	21.86%	21.09%	25.58%
RoCE %*	25.50%	20.24%	19.23%	21.33%
Net Working Capital Days*	49	50	68	40

Notes: EBITDA*, ROCE* and Net Working Capital Days* formula refer to Page no. 142 of Prospectus Link to Prospectus - www.sebi.gov.in/filings/public-issues/may-2023/mankind-pharma-limited-prospectus 71518.html

ESG : Organization wide focus on sustainable growth



Key Highlights Key Initiatives

• 17,468 KL treated waste water sent for reuse

- Zero Reportable Lost time accidents across all manufacturing units
- Started mapping of Scope-3 emissions for Upstream/ Downstream Activities
- Sikkim- 100% of generated Hazardous waste sent to cement plants for its coprocessing for energy recovery
- U1 & U2 Rain water Harvesting structures commissioned

- ESG assessment started for Critical & strategic value chain partners
- ESG Training to internal procurement team & other stakeholders

Key

Priorities

- Supplier Code of conduct to be included in >70% new supplier agreements
- Sikkim- Paddle dryer for sludge moisture reduction

New

Technologies

- Sikkim- ZLD implementation with upgraded technology
- Unit2- High COD (Organic Matter) treatment
- Sikkim- Commissioning of solar panels to increase the share of Renewable energy


Silver Award to Unit-3, Paonta Sahib from Kaizen Hansei under Environment & ESG assessment.



Best Occupational Health and Safety award by Apex India to Unit-1 & Unit-2 of Paonta Sahib







Promoters Mutual Funds FPI & Bodies Corporate Retail Others

BSE Ticker	543904	
NSE Symbol	MANKIND	
Market Cap. (INR Crore)*	70,952	
% Free Float	23.5	
Free Float Market Cap. (INR Crore)	16,674	
Shares Outstanding (crore)	40.06	
Industry	Pharmaceuticals	

Shareholding Pattern & Holding as on 30th June, 2023 * Share Price from NSE as on 1st August, 2023



Date	3 rd August, 2023
Time	12 Noon IST
	Dial – In Details
Universal Access Numbers	+91-22-62801214/ +91-22-71158115
Diamond Pass	https://services.choruscall.in/DiamondPassRegistration/register?confirm ationNumber=9990656&linkSecurityString=35ca196800

Annexure – Formulae



- **ROE** = (Profit for the year) / (average total equity less cash)
 - o Profit excludes interest income and gain on current investments measured at FVTPL
- Adjusted ROE = (Adjusted profit for the year) / (average adjusted total equity less cash)
 - o Profit excludes any M&A related impact, interest income and gain on current investments measured at FVTPL
 - Adjusted total equity excludes Cash, cash used for acquisitions and is adjusted for M&A related impact (net of Tax)
- ROCE = (EBIT for the year) / (Capital employed less cash)
 - EBIT excludes other income
 - Capital employed is the sum of total equity, total borrowings, total lease liabilities and deferred tax liabilities (net) less deferred tax assets and Cash.
- Adjusted ROCE = (Adjusted EBIT for the year)/ (Adjusted Capital employed less cash)
 - Adjusted EBIT excludes M&A related impact and other income
 - Adj. Capital employed is the sum of total equity, total borrowings, total lease liabilities, deferred tax liabilities (net), M&A related impact (net of Tax) less deferred tax assets, Cash and cash used for acquisitions.
- **Cash** = (Cash and cash equivalents + Other bank balances + investment in Mutual funds)
- Net Cash = (Cash Current borrowings Non Current borrowings at the end of the year)
- Net Operating Working Capital Days = (Average operating working capital / Revenue from operations) X 365 days.
 Operating working capital is the sum of Inventories and Trade receivables less Trade payables
- Cash EPS =. Profit/(Loss) for the period plus Depreciation, Amortization and Impairment / weighted average number of equity shares outstanding during the period

Thank You

For more information please visit our website: https://www.mankindpharma.com

For specific queries, contact: Investor Relations - 011 - 46846700 Investor.relations@mankindpharma.com